Form 4: Upstream Bio Director Ratcliffe Acquires Stock Options
SEC Filing
Director Liam Ratcliffe of Upstream Bio, Inc. reports the acquisition of stock options.
Summary
- Liam Ratcliffe, a director of Upstream Bio, Inc., filed a Form 4 with the SEC.
- The filing reports a transaction on October 10, 2024, where Ratcliffe acquired stock options.
- Ratcliffe acquired options to purchase 17,096 shares of common stock at an exercise price of $17.
- The options vest on the earlier of October 10, 2025, or the date of the next Annual Meeting of Stockholders, contingent upon continued service.
- Following the transaction, Ratcliffe directly owns options for 17,096 shares.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, indicating standard insider activity. It doesn't inherently suggest positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 10/10/2024 | Date of stock option acquisition. |
| 10/10/2025 | First possible vesting date for the stock options. |
| 10/09/2034 | Expiration date of the stock options. |
| 10/15/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.